Archive for the ‘Gene Therapy Research’ Category
GROW YOUR HAIR LONG! GIVEAWAY – Video
GROW YOUR HAIR LONG! GIVEAWAY
okay so who want long gorgeous healthy hair!!!!???? SAY I, so I am giving away the whole ovation cell therapy line to one of you lovely ladies so you can be ...
By: REAL BEAUTY by Cynthia
Read more here:
GROW YOUR HAIR LONG! GIVEAWAY - Video
Genetic engineering genes proteomics gene bioinformatics – Video
Genetic engineering genes proteomics gene bioinformatics
By: Iridium
Go here to see the original:
Genetic engineering genes proteomics gene bioinformatics - Video
Exclusive David Gancberg article in Human Gene Therapy
PUBLIC RELEASE DATE:
24-Feb-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, February 24, 2014Over the past three funding stages, the European Commission has invested nearly $475 million in 100 projects in the gene transfer and gene therapy field. David Gancberg, Directorate-General for Research and Innovation, European Commission (Brussels), describes the substantial opportunities for funding to support basic and clinical research in gene and cell therapy to find new treatments for chronic and rare diseases and novel regenerative medicine approaches in a Commentary article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.
Dr. Gancberg and co-author Ruxandra Draghia-Akli state, "More than ever, the European Union offers to the gene and cell therapy sectors the possibilities of financial support to bright and innovative consortia ready to develop, possibly in collaboration with industry, new therapeutic applications to be tested in clinical trials, or novel products for the market, and build sustainable networks of expertise in the field," in their article "Gene and Cell Therapy Funding Opportunities in Horizon 2020: An Overview 2014-2015."
"Funding for gene therapy provided by the European Commission over the last decade has been critical to the current success we are seeing in the clinics. The commentary provided by doctors Gancberg and Draghia-Akli describe exciting new programs." says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
###
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
View post:
Exclusive David Gancberg article in Human Gene Therapy
Is previous hypoglycemia a risk factor for future hypoglycemic episodes?
PUBLIC RELEASE DATE:
24-Feb-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, February 24, 2014The automatic "threshold suspend" (TS) feature of an insulin pump helps prevent life-threatening hypoglycemic events when the device's sensor detects blood glucose concentrations below the preset threshold. However, in individuals with type 1 diabetes who have had previous episodes of hypoglycemia the TS feature may be less effective at preventing subsequent events, according to important new results from the ASPIRE study published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http://www.liebertpub.com/DTT.
In the article "Hypoglycemia Begets Hypoglycemia: The Order Effect in the ASPIRE In-Clinic Study," Editor-in-Chief of Diabetes Technology & Therapeutics Satish Garg, MD (Professor of Medicine and Pediatrics at the University of Colorado Denver) and coauthors compared the effects of an automatic insulin pump with TS at a preset sensor threshold to those of continued basal insulin delivery in adults with type 1 diabetes following induced hypoglycemia via overnight fasting and exercise.
The different outcomes seen between the two insulin delivery methods in this crossover study design led the authors to conclude that "By mitigating the duration of hypoglycemic episodes, automatic pump suspension may help to preserve the normal autonomic response to hypoglycemia in patients with type 1 diabetes."
###
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http://www.liebertpub.com/DTT. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
About ATTD
More here:
Is previous hypoglycemia a risk factor for future hypoglycemic episodes?
Lot 107 Warner Beef Genetics – Video
Lot 107 Warner Beef Genetics
By: Chris Mitchell
View original post here:
Lot 107 Warner Beef Genetics - Video
Lot 119 Warner Beef Genetics – Video
Lot 119 Warner Beef Genetics
By: Chris Mitchell
Read the original post:
Lot 119 Warner Beef Genetics - Video
Lot 145 Warner Beef Genetics – Video
Lot 145 Warner Beef Genetics
By: Chris Mitchell
See the rest here:
Lot 145 Warner Beef Genetics - Video
How to solve genetics problems with forked line method – Video
How to solve genetics problems with forked line method
this is just another way to be able to predict genotype and phenotype ratios in dihybrid problems this way you don #39;t have to write the box but it does requir...
By: GeneticsLessons
Read more from the original source:
How to solve genetics problems with forked line method - Video
Skunk House Genetics 2/22/2014 – Video
Skunk House Genetics 2/22/2014
Skunk House Genetics germination 2/22/2014.
By: New England Grower
Go here to read the rest:
Skunk House Genetics 2/22/2014 - Video
Codex Minecraft Attack of the B-Team | Episode 4: Advanced Genetics – Video
Codex Minecraft Attack of the B-Team | Episode 4: Advanced Genetics
CodexMC members ----------------------- BrhysH: https://www.youtube.com/user/Brhys1 Mr_Ging: https://www.youtube.com/channel/UCoK71ktgWpeKVc-ocW-E8kg Joe Bil...
By: DarkCloudSky7
Original post:
Codex Minecraft Attack of the B-Team | Episode 4: Advanced Genetics - Video
The Social Grow update #2 / Skunk House Genetics…… – Video
The Social Grow update #2 / Skunk House Genetics......
Biker Kush 13 x Pandora #39;s Box...Day 1 of pre-veg.
By: OrganicGrowslife
Continued here:
The Social Grow update #2 / Skunk House Genetics...... - Video
Immune cell therapy may revolutionize leukemia treatment
Washington, Feb. 23 : A team of researchers, who conducted largest ever study of patients with advanced leukemia, have found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells, thus demonstrating that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies.
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study's senior authors said their initial findings have held up in a larger cohort of patients, and they are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were "reeducated" to recognize and destroy cancer cells that contain the protein CD19.
While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body's own immune system to attack and kill cancerous cells.
The study was published in the journal Science Translational Medicine.
--ANI (Posted on 23-02-2014)
Read the original post:
Immune cell therapy may revolutionize leukemia treatment
Genetic engineering good to help with diseases, disabilitie – Video
Genetic engineering good to help with diseases, disabilitie
Good to help people with diseases, disabilities, and deformities.
By: HardKore5250
Originally posted here:
Genetic engineering good to help with diseases, disabilitie - Video
EL PT 2014 Podcast 1 Genetic Engineering Designer Babies – Video
EL PT 2014 Podcast 1 Genetic Engineering Designer Babies
Done by: Pang Cheng Feng(Leader) Lim Wei Feng(Primary Editor) Low Kai Ferng(Video Editor) Jedidiah Cheng(Secondary Editor) Loo Zhong Han(Secondary Editor) Th...
By: Ferng Low
See the original post:
EL PT 2014 Podcast 1 Genetic Engineering Designer Babies - Video
Lot 23 Warner Beef Genetics – Video
Lot 23 Warner Beef Genetics
By: Chris Mitchell
See the original post here:
Lot 23 Warner Beef Genetics - Video
Lot 59 Warner Beef Genetics – Video
Lot 59 Warner Beef Genetics
By: Chris Mitchell
Continue reading here:
Lot 59 Warner Beef Genetics - Video
Lot 69 Warner Beef Genetics – Video
Lot 69 Warner Beef Genetics
By: Chris Mitchell
Follow this link:
Lot 69 Warner Beef Genetics - Video
Mutant Genetics E2 – Video
Mutant Genetics E2
Campaign battle.
By: Anthony Herrera
See the rest here:
Mutant Genetics E2 - Video
Genetics Testing: What Consumers Need to Know with Heather Hampel, MS, CGC – Video
Genetics Testing: What Consumers Need to Know with Heather Hampel, MS, CGC
On this week #39;s segment of Toward a Cancer-Free World, Heather Hampel, a certified genetic counselor at #TheJames, talks with WBNS-10TV about genetic testing.
By: Ohio State University Comprehensive Cancer Center-James Cancer Hospital Solove Research Institute
Continued here:
Genetics Testing: What Consumers Need to Know with Heather Hampel, MS, CGC - Video
Lot 132 Warner Beef Genetics – Video
Lot 132 Warner Beef Genetics
By: Chris Mitchell
See the rest here:
Lot 132 Warner Beef Genetics - Video
Gene therapy a promising tool for cardiac regeneration
After a heart attack, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after blood flow is blocked off to the heart. This partial healing can be attributed to heart disease being one of the leading causes of death. What if the cells could be stimulated to divide and the heart could be induced to repair itself? This was the question posed by George Washington University (GW) researcher Scott Shapiro, M.D., Ph.D., and his co-authors, who found that cardiac regeneration may be a possibility with gene therapy.
The research, published yesterday in Science Translational Medicine, found that gene therapy can elicit a regenerative response in pig hearts. Shapiro and his research team first looked to small animals such as the zebrafish, which are able to regenerate heart tissue after a heart attack. This animal has a key protein at play, Cyclin A2 (Ccna2).
After seeing the effects of CCna2 in small animals, we began looking at the effects of the gene in larger animals, such as pigs, said Shapiro, assistant professor of medicine at the GW School of Medicine and Health Sciences. We delivered Ccna2 directly into the heart and found that pigs not only had improved cardiac function, but also found evidence of cellular regeneration.
Ccna2 is a prenatal gene normally turned off in humans after birth. Shapiro believes using gene therapy as a tool for cardiac regeneration, optimized for humans, could lead to a viable treatment option for patients who suffer from myocardial infarction, or heart attack.
Story Source:
The above story is based on materials provided by George Washington University. Note: Materials may be edited for content and length.
Link:
Gene therapy a promising tool for cardiac regeneration